Zai Lab (NASDAQ: ZLAB) — Company Overview, News & Financial Data
Zai Lab is a biopharmaceutical company focused on developing innovative medicines for oncology and autoimmune disorders.
Zai Lab
Zai Lab (HKEX:9688), (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to meet the needs of patients across a broad range of diseases, including oncology, autoimmune disorders, and infectious diseases. The company emphasizes research and collaboration, aiming to bring cutting-edge treatments to underserved populations. Through its projects, Zai Lab endeavors to push the boundaries of medical science, striving to improve outcomes and enhance the quality of life for patients worldwide. Its objectives center around expanding its product portfolio, advancing its clinical trials, and fostering partnerships to accelerate the global availability of its therapeutic solutions.
Snapshot
Operations
Products and/or services of Zai Lab
- Omvikopa (Niraparib) for the treatment of ovarian cancer, providing a targeted therapy option for patients with specific genetic mutations.
- Optune, a novel electric field therapy for glioblastoma, offering a non-invasive treatment option to improve survival rates in brain cancer patients.
- Repotrectinib, a next-generation ROS1/NTRK inhibitor targeting a broad range of mutations in non-small cell lung cancer and other solid tumors.
- Margetuximab, an innovative monoclonal antibody for HER2-positive breast cancer, designed to provide a more effective treatment option compared to standard therapies.
- Regorafenib, a kinase inhibitor for the treatment of colorectal cancer and gastrointestinal stromal tumors, offering hope to patients with advanced stages of the disease.
- Zejula (Niraparib) for treating endometrial cancer, expanding the use of Niraparib beyond ovarian cancer to benefit a wider range of patients.
Zai Lab executive team
- Ying DuFounder, Chairperson & CEO
- Rafael G. AmadoPresident and Head of Global Research & Development
- Yajing ChenChief Financial Officer
- Frazor Titus Edmondson IIIChief Legal Officer & Corporate Secretary
- Christine ChiouSenior VP & Head of Investor Relations
- James YanChief Operating Officer of Global R&D
- Shan HeSenior VP & Chief Business Officer
Latest news about Zai Lab
Zai Lab reports 81.8% response rate in lung cancer trial
United StatesZai Lab, argenx report 15.4-point ALKIVIA improvement
United StatesZai Lab gains European orphan drug designation
United StatesZai Lab gains China approval for first-of-Its-kind cervical cancer therapy
United StatesChina approves AUGTYRO™ (Repotrectinib) for NTRK-positive solid tumors
United StatesChina approves Zai Lab’s Cobenfy, first new Schizophrenia mechanism in decades
United States
Key financials
Reported results for Zai Lab, in USD.
- Market cap
- 3.3B
- Revenue (TTM)
- 441.7M
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.8
- Dividend yield
- —
- Profit margin
- -44.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 460.2M | -223.6M | -175.5M | |
| 399M | -282.1M | -257.1M | |
| 266.7M | -366.6M | -334.6M | |
| 215M | -404.4M | -443.3M |